Jump to content
Powered by

Selected press releases

  • Press release - 17/11/2020

    The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.

  • Press release - 16/11/2020

    CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.

  • Press release - 09/11/2020

    Sometimes an image is just an image. Sometimes it gives those who can read it correctly a deeper insight into what they can see. In many scientific disciplines, the key to extracting meaningful information from large three-dimensional images, obtained from X-ray tomography or optical microscopy, is segmentation, a tedious and time-consuming – and therefore error-prone – task if done manually.

  • Press release - 09/11/2020

    To ensure that sepsis patients receive appropriate antibiotics as quickly as possible, Fraunhofer IGB researchers have developed a diagnostic procedure that uses high-throughput sequencing of blood samples and delivers results much faster than conventional culture-based techniques. Thanks to the latest single-molecule sequencing techniques, this process has now been further improved so that pathogens can be identified after just a few hours.

  • Press release - 04/11/2020

    The German Childhood Cancer Foundation is providing EUR 2.2m to fund the phase III clinical trial to investigate the treatment options for certain types of childhood brain cancer with a chronic course. Initiated by the Hopp Children’s Cancer Center Heidelberg, the trial will compare two standard chemotherapy treatments and a targeted therapy to establish which is the most effective and well tolerated as a standard therapy for young patients.

  • Press release - 02/11/2020

    CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate.

  • Press release - 26/10/2020

    What role do the lymphatic vessels play in the metastasis of cancer cells? Scientists from the German Cancer Research Center and the Mannheim Medical Faculty of the University of Heidelberg developed a method to investigate this question in mice. The aim of the work was to identify new ways to block the dangerous colonization and spread of tumor cells.

  • Press release - 20/10/2020

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

  • Press release - 15/10/2020

    Tumors of the pancreas are particularly feared. They are usually discovered late and mortality is high. Until now, no targeted and personalized therapies exist. Scientists at the German Cancer Research Center (DKFZ) and the Heidelberg Institute for Stem Cell Technology and Experimental Medicine* (HI-STEM) have now succeeded for the first time in defining two differently aggressive molecular subtypes of pancreatic carcinoma.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/press-release